Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

From concept to delivery: a yeast-expressed recombinant protein-based COVID-19 vaccine technology suitable for global access

30 May 2023

Abstract excerpt

INTRODUCTION: The development of a yeast-expressed recombinant protein-based vaccine technology co-developed with LMIC vaccine producers and suitable as a COVID-19 vaccine for global access is described. The proof-of-concept for developing a SARS-CoV-2 spike protein receptor-binding domain (RBD) antigen as a yeast-derived recombinant protein vaccine technology is described. AREAS COVERED: Genetic Engineering: The...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to SARS-CoV-2 and COVID-19 Research
Share to Transgenic Plants and Applications
Share to vaccines and immunoinformatics approaches

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 37252854
DOI: 10.1080/14760584.2023.2217917

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 9 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

From concept to delivery: a yeast-expressed recombinant protein-based COVID-19 vaccine technology suitable for global accessPMID 37252854Read ↗

Yeast-expressed Recombinant SARS-CoV-2 Receptor Binding Domain, RBD203-N1 as a COVID-19 Protein Vaccine CandidateSemantic proximity Read ↗

Yeast-Based Virus-like Particles as an Emerging Platform for Vaccine Development and DeliverySemantic proximity Read ↗

Translational Virology - COVID-19, The Perfect ExampleSemantic proximity Read ↗

Engineered SARS-CoV-2 receptor binding domain improves manufacturability in yeast and immunogenicity in miceSemantic proximity Read ↗

VLP-Based COVID-19 Vaccines: An Adaptable Technology against the Threat of New VariantsSemantic proximity Read ↗

Prokaryote- and Eukaryote-Based Expression Systems: Advances in Post-Pandemic Viral Antigen Production for VaccinesSemantic proximity Read ↗

Development of Next Generation Vaccines against SARS-CoV-2 and Variants of ConcernSemantic proximity Read ↗

Yeast-produced RBD-based recombinant protein vaccines elicit broadly neutralizing antibodies and durable protective immunity against SARS-CoV-2 infectionSemantic proximity Read ↗

Genetic Modification to Design a Stable Yeast-expressed Recombinant SARS-CoV-2 Receptor Binding Domain as a COVID-19 Vaccine CandidateSemantic proximity Read ↗

A modular protein subunit vaccine candidate produced in yeast confers protection against SARS-CoV-2 in non-human primatesSemantic proximity Read ↗

SARS-CoV-2 RBD219-N1C1: A Yeast-Expressed SARS-CoV-2 Recombinant Receptor-Binding Domain Candidate Vaccine Stimulates Virus Neutralizing Antibodies and T-cell Immunity in MiceSemantic proximity Read ↗

The Role of the Biomanufacturing Industry in Developing Diagnostics and mRNA Vaccines Against COVID-19Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.